Sell-side analysts on Wall Street are anticipating that AEterna Zentaris Inc. (NASDAQ:AEZS) will report earnings of $-1.39 per share when the company issues their quarterly report today. This is the consensus EPS number according to data from Zack’s Research. How the estimated EPS differs from the actual earnings number is what investors will be paying particularly close attention to.
Most recently AEterna Zentaris Inc. (NASDAQ:AEZS) posted a surprise factor of -40%. The actual number was $-2 away from the Zacks consensus immediately prior to the actual release. A significant surprise factor can lead to stock volatility and swings in the share price in the hours and days following the earnings report.
Projected Stock Movement
Research brokerage firms covering shares of AEterna Zentaris Inc. (NASDAQ:AEZS) are anticipating on a consensus basis that the stock will reach $11 within the next 52 weeks. Of the analysts providing short term targets, the most bullish analyst has a $12 target on the stock. On the other end, the most conservative has a short term target of $10. This is based on the 4 analysts taken into consideration by Zacks. The consensus price target was last revised on 2016-03-21.
Zacks also provides a simplified scale for analyst recommendations. They use a one to five scale where they translate brokerage firm Buy/Sell/Hold recommendations into an average broker rating. A low number in the 1-2 range typically indicates a Buy, 3 represents a Hold and 4-5 represents a consensus Sell rating. AEterna Zentaris Inc. (NASDAQ:AEZS) currently has an ABR of 1.25 heading into today’s announcement. This number is also based on the 4 sell-side firms polled by Zacks
Aeterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrine therapy. The Company’s pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. The development priorities in oncology are the completion of Phase 3 trials with perifosine in colorectal cancer (CRC) and in multiple myeloma (MM), as well as the further advancement of AEZS-108, for which it has completed a Phase 2 trial in advanced endometrial and advanced ovarian cancer. Its pipeline also encompasses other earlier-stage programs in oncology. AEZS-112, which is an oral anticancer agent, which includes three mechanisms of action (tubulin, topoisomerase II and angiogenesis inhibition) has completed a Phase 1 trial in advanced solid tumors and lymphoma.
This article is informational purposes only and should not be considered a recommendation to buy or sell the stock